Literature DB >> 21868570

Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers.

Kiran Naqvi1, Elias Jabbour, Carlos Bueso-Ramos, Sherry Pierce, Gautam Borthakur, Zeev Estrov, Farhad Ravandi, Stefan Faderl, Hagop Kantarjian, Guillermo Garcia-Manero.   

Abstract

Patients referred to tertiary care centers occasionally may have their diagnostic procedures repeated and have a final diagnosis that differs from that of the referring center. The aim of this study was to evaluate discordance rates and their clinical implications in the diagnosis of patients with myelodysplastic syndrome (MDS) referred to a tertiary center. We analyzed 915 patients with MDS who were referred to M. D. Anderson Cancer Center between September 2005 and December 2009. Discordance in the diagnosis was documented in 109 (12%) patients, with a majority reclassified as having higher-risk disease by French-American-British (67%) or by International Prognostic Scoring System (77%) with implications for therapy selection and prognosis calculation. These results demonstrate the complexity of the diagnosis of MDS and highlight the need for confirmation of diagnosis when in doubt.

Entities:  

Mesh:

Year:  2011        PMID: 21868570      PMCID: PMC4081364          DOI: 10.1182/blood-2011-03-342642

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  Myelodysplastic syndromes.

Authors:  Ayalew Tefferi; James W Vardiman
Journal:  N Engl J Med       Date:  2009-11-05       Impact factor: 91.245

2.  Comparison of referring and tertiary cancer center physician's diagnoses in patients with leukemia.

Authors:  M DeLima; M Albitar; S O'Brien; S Pierce; H Kantarjian; M Andreeff; L Fayad; M Keating; E Estey
Journal:  Am J Med       Date:  1998-03       Impact factor: 4.965

Review 3.  Hypomethylating agents and other novel strategies in myelodysplastic syndromes.

Authors:  Guillermo Garcia-Manero; Pierre Fenaux
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

4.  International scoring system for evaluating prognosis in myelodysplastic syndromes.

Authors:  P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

5.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Authors:  Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

6.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

7.  Proposals for the classification of the myelodysplastic syndromes.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1982-06       Impact factor: 6.998

8.  Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.

Authors:  Hagop Kantarjian; Jean-Pierre J Issa; Craig S Rosenfeld; John M Bennett; Maher Albitar; John DiPersio; Virginia Klimek; James Slack; Carlos de Castro; Farhad Ravandi; Richard Helmer; Lanlan Shen; Stephen D Nimer; Richard Leavitt; Azra Raza; Hussain Saba
Journal:  Cancer       Date:  2006-04-15       Impact factor: 6.860

Review 9.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

10.  Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts.

Authors:  Ghulam J Mufti; John M Bennett; Jean Goasguen; Barbara J Bain; Irith Baumann; Richard Brunning; Mario Cazzola; Pierre Fenaux; Ulrich Germing; Eva Hellström-Lindberg; Itsuro Jinnai; Atsushi Manabe; Akira Matsuda; Charlotte M Niemeyer; Guillermo Sanz; Masao Tomonaga; Teresa Vallespi; Ayami Yoshimi
Journal:  Haematologica       Date:  2008-10-06       Impact factor: 9.941

  10 in total
  28 in total

1.  Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.

Authors:  Eric J Duncavage; Geoffrey L Uy; Allegra A Petti; Christopher A Miller; Yi-Shan Lee; Bevan Tandon; Feng Gao; Catrina C Fronick; Michelle O'Laughlin; Robert S Fulton; Richard K Wilson; Meagan A Jacoby; Amanda F Cashen; Lukas D Wartman; Matthew J Walter; Peter Westervelt; Daniel C Link; John F DiPersio; Timothy J Ley; John S Welch
Journal:  Blood       Date:  2017-01-12       Impact factor: 22.113

2.  Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents.

Authors:  Elias Jabbour; Paolo Strati; Monica Cabrero; Susan O'Brien; Farhad Ravandi; Carlos Bueso-Ramos; Qiao Wei; Jianhua Hu; Simon Abi Aad; Nicholas J Short; Courtney Dinardo; Naval Daver; Tapan Kadia; William Wierda; Yue Wei; Simona Colla; Gautam Borthakur; Jorge Cortes; Zeev Estrov; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Am J Hematol       Date:  2017-02-13       Impact factor: 10.047

3.  I walk the line: how to tell MDS from other bone marrow failure conditions.

Authors:  Lukasz P Gondek; Amy E DeZern
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

Review 4.  Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics.

Authors:  Aaron C Shaver; Adam C Seegmiller
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

Review 5.  Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.

Authors:  James A Kennedy; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

6.  Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers.

Authors:  Cecilia Arana Yi; Ghayathri Jeyakumar; Pedro Medina; Jorge Cortes; Sherry Pierce; Carlos Bueso-Ramos; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2013-11-13       Impact factor: 3.156

Review 7.  New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice.

Authors:  Zuzana Tothova; David P Steensma; Benjamin L Ebert
Journal:  Clin Cancer Res       Date:  2013-01-17       Impact factor: 12.531

8.  Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?

Authors:  Amer M Zeidan; Thomas Prebet; Ehab Saad Aldin; Steven David Gore
Journal:  Expert Rev Hematol       Date:  2014-02-24       Impact factor: 2.929

9.  Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes.

Authors:  M G Della Porta; E Travaglino; E Boveri; M Ponzoni; L Malcovati; E Papaemmanuil; G M Rigolin; C Pascutto; G Croci; U Gianelli; R Milani; I Ambaglio; C Elena; M Ubezio; M C Da Via'; E Bono; D Pietra; F Quaglia; R Bastia; V Ferretti; A Cuneo; E Morra; P J Campbell; A Orazi; R Invernizzi; M Cazzola
Journal:  Leukemia       Date:  2014-05-20       Impact factor: 11.528

10.  Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.

Authors:  Leonor Senent; Leonor Arenillas; Elisa Luño; Juan C Ruiz; Guillermo Sanz; Lourdes Florensa
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.